Analyst Reco. Krystal Biotech, Inc.

Equities

KRYS

US5011471027

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-25 pm EDT			5-day change	1st Jan Change
155.7 ^USD	-2.12%		-5.06%	+25.49%

Apr. 22	Krystal Biotech, Inc Announces First Patient Dosed in Phase 1 Clinical Trial of Inhaled KB707 for the Treatment of Locally Advanced or Metastatic Solid Tumors of the Lung	CI
Apr. 16	Stifel Adjusts Price Target on Krystal Biotech to $204 From $178, Maintains Buy Rating	MT

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Stifel Adjusts Price Target on Krystal Biotech to $204 From $178, Maintains Buy Rating	Apr. 16	MT
Cantor Fitzgerald Initiates Krystal Biotech With Overweight Rating, Price Target is $160	23-10-24	MT
Citigroup Initiates Krystal Biotech at Buy Rating With $160 Price Target	23-10-12	MT
Berenberg Initiates Coverage on Krystal Biotech at Buy, $154 Price Target	23-09-07	MT
Chardan Ups Price Target on Krystal Biotech to $153 From $148, Keeps Buy Rating	23-08-08	MT
BofA Securities Adjusts Krystal Biotech Price Target to $140 From $118, Maintains Buy Rating	23-05-25	MT
Stifel Increases Price Target on Krystal Biotech to $145 From $102, Maintains Buy Rating	23-05-24	MT
Goldman Sachs Adjusts Price Target on Krystal Biotech to $155 From $135, Keeps Buy Rating	23-05-22	MT
Guggenheim Adjusts Price Target on Krystal Biotech to $130 From $101, Maintains Buy Rating	23-05-22	MT
HC Wainwright Adjusts Price Target on Krystal Biotech to $139 From $119, Keeps Buy Rating	23-05-22	MT
Chardan Raises Price Target on Krystal Biotech to $148 From $133, Keeps Buy Rating	23-05-22	MT
BofA Securities Adjusts Price Target on Krystal Biotech to $118 From $105, Keeps Buy Rating	23-05-22	MT
Stifel Starts Krystal Biotech at Buy With $102 Price Target	23-04-18	MT
Goldman Sachs Upgrades Krystal Biotech to Buy From Neutral, Adjusts Price Target to $124 From $79	23-02-28	MT
Chardan Lifts Price Target on Krystal Biotech to $133 From $130, Reiterates Buy Rating	22-11-08	MT
HC Wainwright Adjusts Price Target on Krystal Biotech to $119 From $107, Maintains Buy Rating	22-11-07	MT
Goldman Sachs Downgrades Krystal Biotech to Neutral From Buy; Price Target is $74	22-08-25	MT
Chardan Research Adjusts Price Target on Krystal Biotech to $130 From $137, Citing Q2 Results, Spend Forecasts; Buy Rating Kept	22-08-09	MT
Goldman Sachs Adjusts Price Target for Krystal Biotech to $78 From $91, Keeps Buy Rating	22-05-24	MT
Guggenheim Adjusts Krystal Biotech's Price Target to $101 From $114, Reiterates Buy Rating	22-03-29	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Analyst Reco. Krystal Biotech, Inc.

Equities

KRYS

US5011471027

Analyst Reco.

Filters